Clinical trial NCT01090414 - References

Chronic Lymphocytic Leukemia — An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

Citation(s)

•   Barrientos J, Coutre SE, et al
  (2014). Long-Term Follow-Up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine, Bendamustine/Rituximab, Fludarabine, Chlorambucil, or Chlorambucil/Rituximab in Patients with Relapsed or Refractory
•   Barrientos JC, Leonard JP, et al
  (2013). Update on a Phase 1 Study of the Selective PI3Kd Inhibitor, Idelalisib (GS-1101) in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory CLL [Presentation]. American Society for C
•   Barrientos JC, Sharman J, et al
  (2012). GS-1101 (CAL-101), A Selective Phosphatidylinositol 3-Kinase-Delta Inhibitor, in Combination With Ofatumumab for the Treatment of Relapsed/ Refractory CLL [Abstract 1062]. Haematologica: the Hematology Journal 17th
•   Barrientos JC, Wagner-Johnston ND, et al
  (2013). Chemo-Immunotherapy Combination of Idelalisib with Bendamustine/Rituximab or Chlorambucil/Rituximab in Patients with Relapsed/ Refractory CLL Demonstrates Efficacy and Tolerability [Poster 4176]. 55th ASH
•   Benson D, Kahl BS, et al
  (2013). Final Results of a Phase 1 Study of Idelalisib, a Selective Inhibitor of PI3Kd, in Patients with Relapsed or Refractory Indolent non-Hodgkin Lymphoma [Presentation]. ASCO Annual Meeting, Chicago, Illinois.
•   Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR
  Idelalisib, an inhibitor of phosphatidylinositol 3-k
•   Brown JR, Cheson BD, et al
  (2015). Patterns of Lymphocytosis in Patients with CLL or Small Lymphocytic Lymphoma (SLL) Treated with Idelalisib. 57th ASH Annual Meeting and Exposition, Orlando, Florida.
•   Brown JR, Furman RR, et al
  (2013). Final Results of a Phase 1 Study of Idelalisib (GS-1101) a Selective Inhibitor of Phosphatidylinositol 3-Kinase p110 Delta (PI3Kd) in Patients with Relapsed or Refractory CLL [Presentation]. ASCO Annual Meeting, Chicago
•   Coutre S, Barrientos C, et al
  (2015). Safety of Idelalisib in B-cell Malignancies: Integrated Analysis of Eight Clinical Trials. ASCO Annual Meeting, Chicago, Illinois.
•   Coutre S, Flinn I, et al
  (2018). Idelalisib in Combination with Rituximab or Bendamustine or Both in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. HemaSphere, 2:3.
•   Coutre S, Leonard J, et al
  (2015). Idelalisib Monotherapy Results in Durable Responses in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia. ASCO Annual Meeting, Chicago, Illinois.
•   DeVos S, Furman RR, et al
  (2013). Idelalisib, a Selective Inhibitor of PI3Kd, in Combination with Bendamustine, Fludarabine, or Chlorambucil in Patients with Relapsed or Refractory (R/R) CLL [Poster 2878]. 55th ASH Annual Meeting and Exposition, New Orle
•   DeVos S, Wagner-Johnston ND, et al
  (2014). Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent non-Hodgkin Lymphoma: Phase I/II Results [Abstract 3063]
•   Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE
  Idelalisib, a selective inhibitor of phosphatidylinositol
•   Furman R, DeVos S, et al
  (2014). Long-Term Follow-Up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab or Ofatumumab) in Patients with Relapsed or Refractory CLL. 56th ASH Annual Meeting and Exposition, San F
•   Furman R, Sharman J, et al
  (2013). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with CLL [Abstract LBA-6]. 55th ASH Annual Meeting and Exposit
•   Ghia P, Cheson BD, et al
  (2016). Patterns of Idelalisib Treatment-Emergent Lymphocytosis in Patients with CLL or SLL [poster]. EHA 21st Congress, Copenhagen, Denmark.
•   Ghia P, Coutre S, et al
  (2016). Management of Transaminase Elevations Associated with Idelalisib [poster]. European Hematology Association (EHA) 21st Congress, Copenhagen, Denmark.
•   Gopal AK, Davies AJ, et al
  (2015). Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory SLL. 57th ASH Annual Meeting and Exposition, Orlando, Florida.
•   Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND
  A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).
•   Leonard JP, Wagner-Johnston ND, et al
  (2013). Combinations of the PI3Kd Inhibitor Idelalisib (GS-1101) with Rituximab and/or Bendamustine are Tolerable and Highly Active in Patients with Previously Treated, Indolent non-Hodgkin Lymphoma: Updated Results
•   Martin P, Armas A, et al
  (2015). Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL). 57th ASH Annual Meeting and Exposition, Orlando, Florida.
•   O'Brien SM, Lamanna N, et al
  (2013). A Phase 2 Study of the Selective Phosphatidylinositol 3-Kinase Delta (PI3Kd) Inhibitor Idelalisib (GS-1101) in Combination with Rituximab in Treatment-Naive Patients = 65 Years with CLL or SLL [Presentation]. ASCO Ann
•   O'Brien SM, Lamanna N, et al
  (2014). Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naive Patients = 65 Years with CLL or SLL [Poster 1994]. 56th ASH Annual Meeting and Exposition, San Francisco, California.
•   O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE
  A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chroni
•   Spurgeon SE, Wagner-Johnston ND, et al
  (2013). Final Results of a Phase 1 Study of Idelalisib, a Selective Inhibitor of Phosphatidylinositol 3-Kinase P110d (PI3Kd) in Patients with Relapsed or Refractory Mantle Cell Lymphoma [Presentation]. ASCO Annual M
•   Wagner-Johnston ND, DeVos S, et al
  (2013). Preliminary Results of PI3Kd Inhibitor Idelalisib (GS-1101) Treatment in Combination with Everolimus, Bortezomib, or Bendamustine/Rituximab in Patients with Previously Treated Mantle Cell Lymphoma [Presentation]
•   Wierda W, Coutre S, et al
  (2016). Management of Transaminase Elevations in Patients Receiving Idelalisib. ASCO Annual Meeting, Chicago, Illinois.

An Extension Study to Investigate the Safety and Durability of Clinical Activity of Idelalisib in Subjects With Hematologic Malignancies

Details for clinical trial NCT01090414